GlobeNewswire·Nov 3, 2026, 7:30 AM ET

BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026

BBIO

BridgeBio Pharma will present two moderated posters, three posters on acoramidis for ATTR-CM, and one BridgeBio-supported poster led by Abbott Laboratories at the AHA Scientific Sessions in Chicago from November 6-9, 2026.
The presented data reinforce acoramidis as a first-line treatment for ATTR-CM due to its profile as the only selective, oral, near-complete (≥90%) transthyretin stabilizer.
Acoramidis is approved as Attruby® by the U.S. FDA and as BEYONTTRA® by the EMA, Japanese PMDA, Swissmedic, Swiss Agency, UK MHRA, Brazilian ANVISA, and Australian TGA.
Moderated presentations include sex-specific ATTR models for diagnosing women with heart failure (presented by Hyewon Jeong) and an AI screening analysis from the TRACE-AI Network (presented by Bruno Batinica) on November 9.
Three poster presentations regarding ATTRibute-CM results will cover effects on heart failure events, risks of hospitalization and mortality, and recovery insights based on NT-proBNP analysis, all presented on November 8.
An Abbott-led poster on detecting tetrameric transthyretin using ARCHITECT c and Alinity c assays will be presented by Lici A. Schurig Briccio on November 9.
Attruby is indicated for treating wild-type or variant ATTR-CM in adults to reduce cardiovascular death and cardiovascular-related hospitalization.
Common adverse reactions for Attruby include diarrhea (11.6% vs 7.6% placebo) and upper abdominal pain (5.5% vs 1.4% placebo), with discontinuation rates of 9.3% for Attruby versus 8.5% for placebo.